Carlos López

11.6k total citations
151 papers, 2.8k citations indexed

About

Carlos López is a scholar working on Oncology, Epidemiology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Carlos López has authored 151 papers receiving a total of 2.8k indexed citations (citations by other indexed papers that have themselves been cited), including 79 papers in Oncology, 41 papers in Epidemiology and 35 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Carlos López's work include Neuroendocrine Tumor Research Advances (34 papers), Lung Cancer Research Studies (30 papers) and Colorectal Cancer Treatments and Studies (26 papers). Carlos López is often cited by papers focused on Neuroendocrine Tumor Research Advances (34 papers), Lung Cancer Research Studies (30 papers) and Colorectal Cancer Treatments and Studies (26 papers). Carlos López collaborates with scholars based in Spain, United States and United Kingdom. Carlos López's co-authors include M. Selim Ünlü, George G. Daaboul, Ming Chen, Molly A. Sullivan, Gregory P. Kalemkerian, James A. Hayman, Randall K. Ten Haken, Feng‐Ming Kong, Matthew J. Schipper and Emre Özkumur and has published in prestigious journals such as Journal of Clinical Investigation, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Carlos López

143 papers receiving 2.8k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Carlos López Spain	30	981	739	675	506	398	151	2.8k
Sung‐Hsin Kuo Taiwan	35	1.2k 1.2×	783 1.1×	1.5k 2.2×	426 0.8×	412 1.0×	231	4.3k
Fabrizio Zanconati Italy	34	712 0.7×	865 1.2×	610 0.9×	268 0.5×	518 1.3×	183	3.6k
Chi Lin United States	26	851 0.9×	310 0.4×	728 1.1×	309 0.6×	327 0.8×	144	2.1k
Masaki Hara Japan	37	617 0.6×	781 1.1×	1.2k 1.8×	336 0.7×	813 2.0×	224	5.2k
Steven E. Finkelstein United States	32	4.0k 4.1×	982 1.3×	998 1.5×	284 0.6×	568 1.4×	71	6.6k
Colleen Simpson United States	14	3.8k 3.9×	1.2k 1.7×	766 1.1×	345 0.7×	510 1.3×	19	7.0k
Charuhas Deshpande United States	27	1.1k 1.1×	486 0.7×	1.2k 1.7×	397 0.8×	240 0.6×	60	3.1k
E. Brian Butler United States	35	1.2k 1.2×	792 1.1×	2.1k 3.1×	394 0.8×	842 2.1×	227	4.7k
Diana M. Cardona United States	27	663 0.7×	799 1.1×	560 0.8×	309 0.6×	143 0.4×	113	2.4k
Chris R. Kelsey United States	35	981 1.0×	395 0.5×	2.5k 3.7×	154 0.3×	1.2k 3.1×	160	3.9k

Countries citing papers authored by Carlos López

Since Specialization

Citations

This map shows the geographic impact of Carlos López's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Carlos López with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Carlos López more than expected).

Fields of papers citing papers by Carlos López

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Carlos López. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Carlos López. The network helps show where Carlos López may publish in the future.

Co-authorship network of co-authors of Carlos López

This figure shows the co-authorship network connecting the top 25 collaborators of Carlos López. A scholar is included among the top collaborators of Carlos López based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Carlos López. Carlos López is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Hernando, Jorge, Javier Molina‐Cerrillo, Rocio García‐Carbonero, et al.. (2025). Data from Cabozantinib plus Atezolizumab in Advanced, Progressive Endocrine Malignancies: A Multicohort, Basket, Phase II Trial (CABATEN/GETNE-T1914). DIGITAL.CSIC (Spanish National Research Council (CSIC)).

Hernando, Jorge, Javier Molina‐Cerrillo, Rocio García‐Carbonero, et al.. (2025). Cabozantinib plus Atezolizumab in Advanced, Progressive Endocrine Malignancies: A Multicohort, Basket, Phase II Trial (CABATEN/GETNE-T1914). Clinical Cancer Research. 31(22). 4655–4663.

Abou‐Alfa, Ghassan K., Mohamed Bouattour, Ann‐Lii Cheng, et al.. (2024). Phase 2/3 study of livmoniplimab in combination with budigalimab in patients with locally advanced or metastatic hepatocellular carcinoma.. Journal of Clinical Oncology. 42(16_suppl). TPS4190–TPS4190. 4 indexed citations

López, Carlos, Mariona Calvo, Juan Carlos Cámara, et al.. (2024). SEOM-GEMCAD-TTD clinical guidelines for the management of hepatocarcinoma patients (2023). Clinical & Translational Oncology. 26(11). 2800–2811. 2 indexed citations

Finn, Richard S., Fabio Piscaglia, T.R. Jeffry Evans, et al.. (2024). Characterization of Tumor Responses in Patients with Unresectable Hepatocellular Carcinoma Treated with Lenvatinib in the Phase 3 Randomized Trial: REFLECT. Liver Cancer. 13(5). 537–547. 1 indexed citations

Alfonso, Pilar, David Páez, Ana Fernández Montés, et al.. (2023). 560MO Maintenance with 5FU/LV-Aflibercept after induction with FOLFIRI-Aflibercept vs FOLFIRI-Aflibercept until progression in older patients (pts) in 2nd line metastatic colorectal cancer (mCRC): The randomized AFEMA trial. Annals of Oncology. 34. S416–S417. 1 indexed citations

Viúdez, A., Emilia Alors‐Pérez, Saioa Goñi, et al.. (2022). Cytokines and Lymphoid Populations as Potential Biomarkers in Locally and Borderline Pancreatic Adenocarcinoma. Cancers. 14(23). 5993–5993. 3 indexed citations

Capdevila, Jaume, Àlex Teulé, Carlos López, et al.. (2020). 1157O A multi-cohort phase II study of durvalumab plus tremelimumab for the treatment of patients (pts) with advanced neuroendocrine neoplasms (NENs) of gastroenteropancreatic or lung origin: The DUNE trial (GETNE 1601). Annals of Oncology. 31. S770–S771. 37 indexed citations

Salvia, Anna La, Jaume Capdevila, Marta Benavent, et al.. (2020). 1159MO Survival and prognostic factors analysis of 535 grade 3 gastroenteropancreatic neuroendocrine neoplasm (GEP-NEN): Data from the Spanish Taskforce of Neuroendocrine Tumours Registry (R-GETNE). Annals of Oncology. 31. S772–S772. 1 indexed citations

10.

López, Carlos, R. Celaya, L.M.M. Ferreira, et al.. (2019). Comparative foraging behaviour and performance between cattle and horses grazing in heathlands with different proportions of improved pasture area. Journal of Applied Animal Research. 47(1). 377–385. 12 indexed citations

11.

Capdevila, Jaume, Oriol Arqués, José Ramón Hernández Mora, et al.. (2019). Epigenetic EGFR Gene Repression Confers Sensitivity to Therapeutic BRAFV600E Blockade in Colon Neuroendocrine Carcinomas. Clinical Cancer Research. 26(4). 902–909. 28 indexed citations

12.

Lamarca, Ángela, Maxime Ronot, Salma Moalla, et al.. (2019). Tumor Growth Rate as a Validated Early Radiological Biomarker Able to Reflect Treatment-Induced Changes in Neuroendocrine Tumors: The GREPONET-2 Study. Clinical Cancer Research. 25(22). 6692–6699. 22 indexed citations

13.

Puente, Ángela, José Ignacio Fortea, Patrícia Huelin, et al.. (2019). Porto-Sinusoidal Vascular Disease Associated to Oxaliplatin: An Entity to Think about It. Cells. 8(12). 1506–1506. 20 indexed citations

14.

Feliú, Jaime, Rocio García‐Carbonero, Jaume Capdevila, et al.. (2019). VITAL phase 2 study: Upfront 5‐fluorouracil, mitomycin‐C, panitumumab and radiotherapy treatment in nonmetastatic squamous cell carcinomas of the anal canal (GEMCAD 09‐02). Cancer Medicine. 9(3). 1008–1016. 8 indexed citations

15.

González‐Flores, Encarnación, Rafael Serrano del Rosal, Isabel Sevilla, et al.. (2018). SEOM clinical guidelines for the diagnosis and treatment of gastroenteropancreatic and bronchial neuroendocrine neoplasms (NENs) (2018). Clinical & Translational Oncology. 21(1). 55–63. 13 indexed citations

16.

Ferreira, L.M.M., Carlos López, R. Celaya, K. Osoro, & M.A.M. Rodrigues. (2017). Effects of animal species and diet composition on long‐chain alcohol faecal recoveries and accuracy of subsequent diet composition estimates. Grass and Forage Science. 73(2). 355–367. 2 indexed citations

17.

López, Carlos, L.M.M. Ferreira, U. García, et al.. (2017). Diet selection and performance of horses grazing on different heathland types. animal. 11(10). 1708–1717. 12 indexed citations

18.

López, Carlos, et al.. (2013). El ganado caballar en los montes asturianos: I Conducta alimentaria y productiva en matorrales de brezal-tojal. 27–34.

19.

Feng, Felix Y., Carlos López, Daniel P. Normolle, et al.. (2007). Effect of Epidermal Growth Factor Receptor Inhibitor Class in the Treatment of Head and Neck Cancer with Concurrent Radiochemotherapy In vivo. Clinical Cancer Research. 13(8). 2512–2518. 41 indexed citations

20.

Park, James O., Carlos López, Vinay Gupta, et al.. (2002). Transcriptional control of viral gene therapy by cisplatin. Journal of Clinical Investigation. 110(3). 403–410. 36 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact